Your browser doesn't support javascript.
loading
Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson's Syndrome: A Case Report.
Mirallas, Oriol; Filippi-Arriaga, Francesca; Hernandez Hernandez, Irene; Aubanell, Anton; Chaachou, Anas; Garcia-Alvarez, Alejandro; Hernando, Jorge; Martínez-Saez, Elena; Biagetti, Betina; Capdevila, Jaume.
Affiliation
  • Mirallas O; Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Filippi-Arriaga F; Clinical Pharmacology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Hernandez Hernandez I; Endocrinology & Nutrition Service, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Aubanell A; Radiology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Chaachou A; Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Garcia-Alvarez A; Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Hernando J; Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Martínez-Saez E; Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Biagetti B; Endocrinology & Nutrition Service, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Capdevila J; Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Front Endocrinol (Lausanne) ; 12: 731631, 2021.
Article in En | MEDLINE | ID: mdl-34858324
ABSTRACT
Nelson's syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing's disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson's syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Adenoma / Nelson Syndrome Type of study: Prognostic_studies Limits: Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Front Endocrinol (Lausanne) Year: 2021 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Adenoma / Nelson Syndrome Type of study: Prognostic_studies Limits: Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Front Endocrinol (Lausanne) Year: 2021 Document type: Article Affiliation country:
...